ArticleBMC cancer2025
ENTR1 affects the progression of colon cancer by regulating energy metabolism under the influence of glycolysis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEndosome-associated trafficking regulator 1 (ENTR1), also known as Serologically Defined Colon Cancer Antigen 3 (SDCCAG3), was initially identified in colon cancer and plays a crucial role in protein transport. Preliminary studies indicate that ENTR1 is involved in the growth of certain tumor types.
methodsIn this study, we analyzed ENTR1 expression levels in normal and tumor tissues using clinical sample data from multiple databases. We also employed Mendelian randomization (MR) analysis of ENTR1. Finally, we conducted in vitro experiments to validate the effects of ENTR1 on colon cancer proliferation and glycolysis.
resultsOur findings reveal that ENTR1 is upregulated in most tumors. Summary-data-based Mendelian Randomization (SMR) analysis indicates a causal relationship between ENTR1 and colon cancer. Further machine learning and metabolite-based Mendelian randomization suggest that ENTR1 may influence tumor growth by regulating glycolysis. Further cellular experiments confirm that knocking out ENTR1 reduces the proliferation of HCT-116 cells and downregulates the expression levels of key glycolytic enzymes.
conclusionsThis study uncovers the role of ENTR1 in various cancers and demonstrates that ENTR1 may promote colon cancer growth by regulating glycolysis, providing a new target for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.